Drugs / SNC-102
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02384369 | Jun 2016 → Jun 2017 | post-traumatic stress disorder | Synchroneuron Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02217007 | Apr 2015 → Jan 2016 | Tourette syndrome | Synchroneuron Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02064010 | Feb 2014 → Jan 2015 | tardive dyskinesia | Synchroneuron Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNC-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02384369 ↗ |
| Route | Oral | “administered orally” NCT02064010 ↗ |